




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : <b>A61K 31/495, A61P 23/00</b>	<b>A1</b>	(11) International Publication Number: <b>WO 00/38684</b> (43) International Publication Date: 6 July 2000 (06.07.00)
<p>(21) International Application Number: PCT/US99/31087</p> <p>(22) International Filing Date: 28 December 1999 (28.12.99)</p> <p>(30) Priority Data: 09/222,844 30 December 1998 (30.12.98) US</p> <p>(71) Applicant: ALLERGAN SALES, INC. [US/US]; 2525 Dupont Drive, Irvine, CA 92612 (US).</p> <p>(72) Inventors: BURKE, James, A.; 2409 E. Avalon Avenue, Santa Ana, CA 92705 (US). GARST, Michael, E.; 2627 Raqueta, Newport Beach, CA 92660 (US). WHEELER, Larry; 18 Valley View, Irvine, CA 92715 (US).</p> <p>(74) Agents: BARAN, Robert, J. et al.; Allergan Sales, Inc., 2525 Dupont Drive, Irvine, CA 92612 (US).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	

(54) Title: (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES FOR THE TREATMENT OF PAIN



## (57) Abstract

A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having formula (I), and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R<sub>1</sub> and R<sub>2</sub> each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MM	Myanmar	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroun	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LJ	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

## (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES FOR THE TREATMENT OF PAIN


Related Applications

This is a continuation-in-part of Application Serial No. 09/012,517, filed January 23, 1998, which is a division of Application Serial No. 08/636,740, filed April 19, 1996, which is a division of Application Serial No. 08/458,949, filed June 2, 1995, which is a division of Application Serial No. 08/390,265, filed February 15, 1995, which is a continuation of application Serial No. 08/135,716, filed October 13, 1993.

Background of the Invention

The present invention relates to certain derivatives of quinoxaline. More particularly, the invention relates to methods of using such derivatives as therapeutic agents, for example, to effect reduction in peripheral pain, to anesthetize the central nervous system, to constrict one or more blood vessels, to treat ischemia, to decongest one or more nasal passages, and to effect reduction of one or more effects of an inflammatory disorder to increase renal fluid flow and to effect an alteration in the rate of fluid transport in the gastrointestinal tract.

Various quinoxaline derivatives have been suggested as therapeutic agents. For example, Danielewicz, et al U.S. Patent 3,890,319 discloses compounds as regulators of the cardiovascular system and, in particular, in the treatment of hypertension, which have the following formula:




where the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- position of the quinoxaline nucleus; X, Y and Z may be in any of the remaining 5-, 6-, 7- or 8- positions and may be selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either the 2- or 3- position of the quinoxaline nucleus and may be hydrogen,

lower alkyl or lower alkoxy. Gluchowski U.S. Patent 5,021,416 discloses the use of similar quinoxaline derivatives to reduce or maintain the intraocular pressure in a mammalian eye. There is no suggestion in either of these patents that such compounds are useful in reducing peripheral pain, as central nervous system anesthetics, as vaso-constricting agents, to treat ischemia, as a nasal passage decongestant, to treat inflammatory disorders, to increase renal fluid flow or to alter the rate of fluid flow in the gastrointestinal tract.

#### 10 Summary of the Invention

New methods for treating mammals, preferably human beings, to provide a desired therapeutic effect have been discovered. By administering an effective amount of one or more of certain compounds to a mammal, a desired therapeutic effect is provided in the mammal. Such desired therapeutic effects include reduction in peripheral pain, that is reduction in acute peripheral and/or reduction in chronic peripheral pain, anesthetization of the central nervous system, constriction of one or more blood vessels, reduction in or prevention of at least one effect of ischemia, decongestion of one or more nasal passages, reduction in at least one effect of an inflammatory disorder, increase in renal fluid flow, and alteration, preferably decrease, in the rate of fluid transport in the gastrointestinal tract.

25 The quinoxaline derivatives useful in the present invention are those quinoxaline derivatives having the formula



, pharmaceutically acceptable acid addition salts thereof and mixtures thereof. R<sub>1</sub> and R<sub>2</sub> each is independently selected from the group consisting of H, alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms.

$R_2$  is preferably a methyl radical. The 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- and 8- positions, preferably in the 6- position, of the quinoxaline nucleus.  $R_1$ ,  $R_4$  and  $R_5$  each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms.  $R_3$  is preferably in the 5- position of the quinoxaline nucleus, and  $R_4$  and  $R_5$  are preferably both H. In a particularly useful embodiment  $R_1$  is Br.

In one embodiment,  $R_1$  is H and  $R_2$  is selected from alkyl radicals containing 1 to 4 carbon atoms.  $R_3$  may advantageously be in the 5- position of the quinoxaline nucleus and be selected from H and alkyl radicals containing 1 to 3 carbon atoms.

All stereoisomers, tautomers and mixtures thereof which comply with the constraints of one or more of the presently useful compounds are included within the scope of the present invention.

Pharmaceutically acceptable acid addition salts of the compounds of the invention are those formed from acids which form non-toxic addition salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, sulfate, or bisulfate, phosphate or acid phosphate, acetate, maleate, fumarate, oxalate, lactate, tartrate, citrate, gluconate, saccharate and p-toluene sulphonate salts.

#### Detailed Description of the Invention

The present invention involves methods for treating mammals to provide one or more desired therapeutic effects in the mammal. The present methods comprise administering an effective amount to provide the desired therapeutic effect or effects in a mammal of at least one compound, as described herein, to the mammal. Among the desired therapeutic effects are reduction in peripheral pain, that is reduction in acute peripheral pain and/or reduction in chronic peripheral pain,

anesthetization of the central nervous system, constriction of one or more blood vessels, reduction in or prevention of at least one effect of ischemia, decongestion of one or more nasal passages, reduction in  
5 at least one effect of an inflammatory disorder, for example, such disorders characterized by progressive joint and/or tissue deterioration, increase in renal fluid flow, and alternation, preferably decrease, in the rate of fluid transport in the gastrointestinal tract. Thus, for  
10 example, the presently useful compounds may be effective as one or more of the following: a peripheral pain killing agent, a general anesthetic, a vaso-constricting agent, an agent for the treatment of ischemia, a nasal decongestant, an anti-inflammatory agent, a medication for use in the  
15 treatment or management of kidney disease, and an anti-diarrhea agent. One important feature of many of the present methods is that the desired therapeutic effect is achieved with reduced side effects, in particular with reduced effects on the blood pressure of the mammal to  
20 which the presently useful compound or compounds are administered.

Any suitable method of administering the presently useful compound or compounds to the mammal to be treated may be used. The particular method of administration  
25 chosen is preferably one which allows the presently useful compound or compounds to have the desired therapeutic effect in an effective manner, e.g., low medication concentration and low incidence of side effects. In many applications, the presently useful compound or compounds  
30 are administered to a mammal in a manner substantially similar to that used to administer alpha agonists, in particular alpha 2 agonists, to obtain the same or similar therapeutic effect or effects.

Administration of the presently useful compounds for  
35 use in the methods of this invention can include, but are

not limited to, oral, parenteral, topical, intra-articular and other modes of systemic administration. The compounds are administered in a therapeutically effective amount either alone or in combination with a suitable  
5 pharmaceutically acceptable carrier or excipient.

Depending on the intended mode of administration, the presently useful compound or compounds may be incorporated in any pharmaceutically acceptable dosage form, such as for example, tablets, suppositories, pills, capsules,  
10 powders, liquids, suspensions, emulsions, aerosols or the like, preferably in unit dosage forms suitable for single administration of precise dosages, or sustained release dosage forms for continuous controlled administration. Preferably, the dosage form will include a  
15 pharmaceutically acceptable excipient and the presently useful compound or compounds and, in addition, may contain other medicinal agents, pharmaceutical agents, carriers, adjuncts, etc.

For solid dosage forms, non-toxic solid carriers  
20 include, but are not limited to, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, the polyalkylene glycols, talcum, cellulose, glucose, sucrose and magnesium carbonate. An example of a solid dosage form for carrying out the invention is a  
25 suppository containing propylene glycol as the carrier. Liquid pharmaceutically administrable dosage forms can, for example, comprise a solution or suspension of one or more of the presently useful compounds and optional pharmaceutical adjuncts in a carrier, such as for  
30 example, water, saline, aqueous dextrose, glycerol, ethanol and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying  
35 agents, pH buffering agents and the like. Typical

examples of such auxiliary agents are sodium acetate, sorbitan monolaurate, triethanolamine, sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, 16th Edition, 1980. The composition of the formulation to be administered, in any event, contains a quantity of one or more of the presently useful compounds in an amount effective to provide the desired therapeutic effect.

Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol and the like. In addition, if desired, the injectable pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like.

The amount of the presently useful compound or compounds administered is, of course, dependent on the therapeutic effect or effects desired, on the specific mammal being treated, on the severity and nature of the mammal's condition, on the manner of administration, on the potency and pharmacodynamics of the particular compound or compounds employed, and on the judgement of the prescribing physician. The therapeutically effective dosage of the presently useful compound or compounds is preferably in the range of about 0.5 or about 1 to about 100 mg/kg/day.

The presently useful compounds are as described

above. The presently useful compounds may be prepared in accordance with the procedures described in Danielewicz, et al U.S. Patent 3,890,319 for the production of the quinoxaline derivatives therein. This patent is hereby  
5 incorporated in its entirety by reference herein.

Briefly, the presently useful 2-imidazolin-2-ylamino quinoxaline derivatives may be prepared by (1) reaction of the appropriate amino-quinoxaline with thiophosgene to form the corresponding isothiocyanate; and (2) reacting  
10 this isothiocyanate with excess ethylene diamine to form the corresponding beta-aminoethyl-thioureidoquinoxaline, which is then cyclized to the corresponding derivative. Alternately, such derivatives can be prepared by (1) reacting the corresponding aminoquinoxaline with benzoyl  
15 isothiocyanate to form the corresponding N-benzoyl thioureido compound, followed by hydrolysis to the thioureido compound, or reaction of the aminoquinoxaline with ammonium thiocyanate to form the thioureido compound directly; (2) methylation to form the S-methyl derivative  
20 of the thioureido compound; and (3) reaction with ethylene diamine to form the derivative.

For derivatives in which the R<sub>3</sub> group is to be alkyl, the corresponding bromo derivative can be produced and than subjected to an alkylation reaction in which the  
25 bromo group is replaced by the desired alkyl group. This alkylation reaction is conveniently conducted using an alkylation agent, such as an alkyl metallic component, e.g., alkyl stannane, in the presence of a platinum group metal-containing catalyst. For example, if it is desired  
30 to substitute a methyl group for the bromo group, the bromo derivative is contacted with tetramethyl tin in the presence of a palladium-containing catalyst, e.g., (Ph<sub>3</sub>P)<sub>2</sub>PdCl<sub>2</sub>, at conditions to effect the desired alkylation or substitution.

35 The following non-limiting examples illustrate

certain aspects of the present invention.

EXAMPLE 1

Preparation of 6-(2-imidazolin-2-ylamino) quinoxaline  
1,2,4-Triaminobenzene dihydrochloride

5 To a suspension of 4-nitrophenylenediamine (Aldrich, 10 g, 65.3 mmol) in absolute ethanol (240 ml) was added 600 mg of 10% by weight palladium on charcoal catalyst. The container including the suspension was evacuated and filled with hydrogen three times and the suspension was  
10 hydrogenated at 18 psi until hydrogen uptake ceased. The reaction was slightly exothermic and one refill of hydrogen was required. The resulting light yellow solution, which darkens rapidly on contact with air, was filtered and concentrated to about 150 ml. Concentrated  
15 hydrochloric acid (12 ml) was added and the solid formed was filtered off. After drying in vacuo overnight, 12 g (a yield of 93%) of purple solid was obtained, m.p. 224-5° C. Using various analytical procedures, this solid was determined to be 1,2,4-triaminobenzene dihydrochloride.

20 6-Aminoquinoxaline

Glyoxal sodium bisulfite adduct (Aldrich, 14.3g, 50 mmol) was added in small portions to a solution of 1,2,4-triaminobenzene dihydrochloride (9.8 g, 50 mmol) in 200 ml of 10% by weight sodium carbonate in water. The reaction  
25 mixture was heated to 100° C for two hours and then cooled to 0° C. The crystals formed were filtered off and dried in vacuo to give a crude yield of 7.06 g (a yield of 97%) of brown crystals. Recrystallization from benzene gave 6.32 g (a yield of 87%) yellow crystals, m.p. 157-8° C.  
30 Using various analytical procedures, these yellow crystals were determined to be 6-aminoquinoxaline.

6-(2-imidazolin-2-ylamino) quinoxaline

6-Aminoquinoxaline (1.00 g, 7.5 mmol) was suspended in 15 ml of water and thiophosgene (0.64 ml, 8.4 mmol) was  
35 added in small portions with vigorous stirring. The

- starting material dissolved and after 2 hours the red color of the solution was discharged. The solid formed was removed by vacuum filtration and washed with water. The crude isothiocyanate thus obtained was used without
- 5 further purification. A solution of the isothiocyanate in benzene (70 ml) was contacted with ethylenediamine (Aldrich, 2.71 g, 45 mmol) in 10 ml of benzene at 25°C for 30 minutes. After stirring for an additional 30 minutes, the supernatant was poured off. The crude thiourea thus
- 10 obtained was washed three (3) times with 10 ml dry ether and used directly for the next step. The crude product was dissolved in 30 ml of dry methanol and the dark green solution was heated at reflux for 15 hours until hydrogen sulfide gas was no longer evolved. The mixture was cooled
- 15 to room temperature and concentrated in vacuo. The resulting dark green solid was chromatographed ( $\text{SiO}_2$ , 90/10  $\text{CHCl}_3/\text{CH}_3\text{OH}$  saturated with  $\text{NH}_3$  (g)) to yield a dark green solid which was recrystallized from  $\text{CH}_3\text{OH}$  to yield 1.11 g of the title compound as a light green crystalline
- 20 solid, mp 232-234° C. The yield was 70%. The compound was characterized by  $^1\text{H}$  and  $^{13}\text{CNMR}$ , IR and mass spectral analysis.

#### EXAMPLE 2

- Preparation of 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline
- 25

##### 6-Amino-5-bromoquinoxaline hydrobromide

- 6-Aminoquinoxaline (2.08 g, 14.4 mmol) was dissolved in 11.5 ml glacial acetic acid. The solution was cooled in water while a solution of bromine (0.74 ml, 2.3g, 14.4
- 30 mmol) in 1.5 ml glacial acetic acid was added slowly over 15 min. After stirring for an additional 30 min, the orange red solid formed was filtered off and washed thoroughly with dry ether. The solid was dried in vacuo overnight to yield 4.44 g crude product (a yield of 100%).
- 35 The compound, 6-amino-5-bromoquinoxaline hydrobromide, had

no definite melting point. A phase change (from fine powder to red crystals) was noticed at about 220° C. Decomposition was observed at about 245° C. It was used directly for the next step.

5 6-Amino-5-Bromoquinoxaline

The crude 6-amino-5-bromoquinoxaline from above was dissolved in water and saturated sodium bisulfite solution was added until the resulting solution tested negative with starch-iodide paper. The solution was then basified  
10 with 2N sodium hydroxide and extracted thoroughly with ethyl acetate. The organic extract was dried over magnesium sulfate and concentrated under reduced pressure to give the free base. The crude product was recrystallized from boiling benzene to give yellow  
15 crystals, m.p. 155-6° C. Using various analytical procedures, the yellow crystals were determined to be 6-amino-5-bromoquinoxaline. The yield was 82%.

5-Bromo-6-isothiocyanatoquinoxaline

20 The crude hydrobromide product previously noted (4.27g, 14.0 mmol) was dissolved in 60 ml of water and thiophosgene (Aldrich, 1.28 ml, 16.8 mmol) was added in small portions with vigorous stirring. After 2 hours, the red color of the solution was discharged. The solid  
25 formed was filtered off and washed thoroughly with water. After drying in vacuo at 25° C, 3.38 g (a yield of 90%) of brick red crystals was obtained, m.p. 157-8° C. A portion of this material was further purified by column chromatography to give white crystals, m.p. 157-8° C.  
30 Using various analytical procedures, these crystals were determined to be 5-bromo-6-isothiocyanatoquinoxaline.

5-Bromo-6(-N-(2-aminoethyl)thioureido)quinoxaline

A solution of the isothiocyanate (3.25 g, 12.2 mmol) in 145 ml benzene was added to a solution of  
35 ethylenediamine (Aldrich, 5.43 g, 90.0 mmol) in 18 ml

benzene at 25° C over 2 hours. After stirring for a further 30 min., the supernatant was poured off. The oil which remained was washed by swirling with dry ether three times and used directly for the next step.

- 5 A portion of this product was further purified by column chromatography (SiO<sub>2</sub>, CHCl<sub>3</sub>) for characterization. A white solid was recovered which decomposed at 175° C with gas evolution (puffing). This white solid was determined to be 5-bromo-6-(N-2-  
10 (aminoethyl)thioureido) quinoxaline.

5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline

The crude product from above was dissolved in 100 ml dry methanol and the brown solution was refluxed for 19 hours until hydrogen sulfide gas was no longer evolved.

- 15 The mixture was cooled to room temperature and concentrated to about 50 ml. The yellow solid was filtered off and dried in vacuo; weight 2.52 g (a yield of 70%), mp 242-4° C.

- As the crude product was insoluble in most common  
20 organic solvents, initial purification was achieved by an acid-base extraction procedure. 23 g of the crude product was dissolved in 100 ml 0.5N hydrochloric acid. The turbid yellow solution was filtered to give a clear orange yellow solution which was extracted twice with ethyl  
25 acetate (2 X 10 ml). The aqueous phase was cooled to 0° C and basified with 6N sodium hydroxide, keeping the temperature of the solution below 15° C at all times. The yellow solid which precipitated was filtered off and washed thoroughly with water until the washings were  
30 neutral to pH paper. The solid was dried overnight in vacuo to give 1.97 g yellow solid, m.p. 249-50° C. The recovery was about 88%.

- Further purification was achieved by recrystallization as described below. The partially  
35 purified product from above was dissolved in N, N-

- dimethylformamide (about 17 ml/g) at 100° C with vigorous stirring. The solution was filtered hot and set aside to cool overnight. The bright yellow crystals were collected by filtration, m.p. 252-3° C. Recovery was from 65-77%.
- 5 Using various analytical procedures, the bright yellow solid was determined to be 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline.

#### EXAMPLE 3

- Preparation of 5-Methyl-6-(2-imidazolin-2-ylamino)quinoxaline
- 10

- A sealable reaction tube was charged with 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline (104 mg., 0.36 mmol) (prepared as noted above), tetramethyl tin (214 mg., 1.2 mmol) and (Ph<sub>3</sub>P),PdCl<sub>2</sub> (10 mg) and dry dimethylformamide (2 ml) in a reaction tube. The reaction mixture was purged with dry nitrogen gas. The tube was sealed and heated to 145° C for 6 hours. The reaction mixture was cooled to room temperature and the solvent removed in vacuo. The dark brown residue was chromatographed (SiO<sub>2</sub>; 5/1 CHCl<sub>3</sub>/CH<sub>3</sub>OH saturated with NH<sub>3</sub> (g)) to yield 46.5 mg (53%) of the title compound as a light yellow solid. An analytical sample was prepared by recrystallization from CHCl<sub>3</sub>/CH<sub>3</sub>OH and had a melting point of 183-186°C. The title compound was characterized by <sup>1</sup>H and <sup>13</sup>CNMR, IR and mass spectral analysis.
- 15
- 20
- 25

#### EXAMPLE 4

Preparation of 2-Methyl-5-bromo-6-(2-imidazolin-2-ylamino)-quinoxaline

2-Methyl-6-nitroquinoxaline

- A solution of pyruvic aldehyde (Aldrich, 40% solution in H<sub>2</sub>O, 11.8 g, 65.3 mmol) was added dropwise to a solution of 4-nitro-1,2-phenylenediamine (Aldrich, 10g, 65.3 mmol) in 150 ml of H<sub>2</sub>O. The reaction mixture was heated to 80° C for four hours. The reaction was cooled to room temperature, diluted with water and extracted with
- 30
- 35

CHCl<sub>3</sub>. The organic extracts were dried over MgSO<sub>4</sub> and evaporated to yield 10.7 g (a yield of 87%) of as a brick red solid. Using various analytical procedures, this solid was determined to be 2-methyl-6-nitroquinoxaline.

5 2-Methyl-6-Aminoquinoxaline

A thick-walled Parr hydrogenation flask was charged with 2-methyl-6-nitroquinoxaline (10.0g, 52.9) and CH<sub>3</sub>OH (200 ml). The flask was flushed with a stream of nitrogen and 10% by weight palladium on charcoal (500 mg) was added. The flask was pressurized with hydrogen to 50 psi and maintained at this pressure for three (3) hours. The reaction mixture was filtered and washed through silicon dioxide and concentrated in vacuo to yield a tan solid. The crude material was chromatographed (SiO<sub>2</sub>; 95/5 CHCl<sub>3</sub>/CH<sub>3</sub>OH saturated with NH<sub>3</sub> (g)) and recrystallized from benzene to yield 7.4 g (a yield of 88%) of a tan solid. Using various analytical procedures, this tan solid was determined to be 2-methyl-6-aminoquinoxaline.

15 2-Methyl-5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline

20 By a series of reaction steps analogous to the reaction steps described above in Example 2 to produce 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline, the title compound (mp. 260° C) was prepared starting with 2-methyl-6-aminoquinoxaline in place of 6-aminoquinoxaline.

25 EXAMPLE 5

Preparation of 3-Methyl-5-bromo-6-(2-imidazolin-2-ylamino)-quinoxaline

3-Methyl-6-aminoquinoxaline

Pyruvic aldehyde (Aldrich, 892 mg, 4.95 mmol, 40% solution H<sub>2</sub>O) was added dropwise to a stirred solution of 1, 2, 4-triaminobenzene hydrochloride (1.0 g, 4.95 mmol) dissolved in 10% aqueous Na<sub>2</sub>CO<sub>3</sub> (15 ml). The mixture was heated at 100° C for two hours before cooling to room temperature. The mixture was extracted with CHCl<sub>3</sub>. The combined organic extracts were dried over MgSO<sub>4</sub> and

concentrated in vacuo to yield a brown solid. The crude product was chromatographed ( $\text{SiO}_2$ , 95/5  $\text{CHCl}_3/\text{CH}_3\text{OH}$  saturated with  $\text{NH}_3$  (g)) to yield 616 mg (a yield of 75%) of a yellow crystalline solid. An analytical sample was prepared by recrystallization from benzene, mp 170-173° C. Using various analytical procedures, the solid was determined to be 3-methyl-6-aminoquinoxaline.

3-Methyl-5-bromo-6-(2-imidazolin-2-ylamino)-quinoxaline

By a series of reaction steps analogous to the reaction steps described above in Example 2 to produce 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline, the title compound (mp > 260° C) was prepared starting with 3-methyl-6-aminoquinoxaline in place of 6-aminoquinoxaline.

EXAMPLE 6

Preparation of 2,3-dimethyl-5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline.

2,3-Dimethyl-6-aminoquinoxaline

2,3-butanedione (7.03 g, 81.7 mmol) was added to a solution of 1,2,4-triaminobenzene hydrochloride (16.5 g, 81.7 mmol) in aqueous 10%  $\text{Na}_2\text{CO}_3$  (200 ml). The reaction mixture was stirred at room temperature for 15 minutes during which time a yellow precipitate formed. The reaction mixture was stirred for an additional 30 minutes before collecting the solid by vacuum filtration. The solid was washed with water, dried in vacuo and chromatographed ( $\text{SiO}_2$ , ethylacetate) to yield 11.7 g (86%) of a tan solid, mp 185-186°C. Using various analytical procedures, this solid was determined to be 2,3-dimethyl-6-aminoquinoxaline.

2,3-dimethyl-5-bromo-6-(2-imidazolin-2-ylamino)-quinoxaline

By a series of reaction steps analogous to the reaction steps described above in Example 2 to produce 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline, the title compound (mp 252-254°C) was prepared starting with 2,3-

dimethyl-6-aminoquinoxaline in place of 6-aminoquinoxaline.

EXAMPLE 7

The final quinoxaline derivative produced in Example 2, that is 5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline, was tested for central nervous system anesthetization activity as follows.

Two (2) animal models were utilized to determine the central nervous system anesthetization activity of the quinoxaline derivative produced in Example 2.

The first of these animal models is identified generally as the mouse hexobarbital sleep time test. Briefly, the compound in question (in a dosage range of between 10 and 500 micrograms/kg, i.v.) and the barbiturate hexobarbital (75 mg/kg, i.p) are coadministered to mice weighing 20 to 22 grams. The hexobarbital produces sleep which lasts for 10 to 14 minutes. Compounds which have central nervous system anesthetization activity potentiate the sleep time induced by hexobarbital. Sleep time is assessed as the time associated with the loss of the animal's reflex to right itself when placed on its back. The  $ED_{50}$  is estimated from dose-response data as the effective dose which potentiates sleep time by 15 minutes. The second animal model used is identified generally as the rat activity test. Briefly, rats weighing 140 to 160 grams are placed into an environmentally isolated activity monitor five (5) minutes following administration of the compound in question (in the range of 1 to 1000 micrograms/kg, i.v.). Horizontal activity, measured in counts is determined for five (5) minutes. A dose-related loss of activity is obtained and fitted to an algorithm to estimate the  $ID_{50}$  which is the dose which decreases activity by 50%.

The final quinoxaline derivative produced in Example 2 was tested using both of the above-noted animal models.

For comparison purposes, clonidine and its hydrophilic analog, p-amino-clonidine, were also tested using these animal models.

Results of these tests are shown in the following table.

Compound	ED <sub>50</sub> (µg/kg) Mouse Sleep-Time	ID <sub>50</sub> (µg/kg) Rat Activity
Clonidine	75	26
p-Amino Clonidine	>500	302
Example 2	116	77

These data demonstrate that the quinoxaline derivative produced in Example 2 has substantial central nervous system anesthetization activity. In particular, the Example 2 compound has a similar degree of such activity as clonidine, which is known to exhibit significant anesthetization activity, and has substantially more of such activity than the hydrophilic analog of clonidine.

#### EXAMPLES 8 TO 13

The final quinoxaline derivative produced in each of Examples 1 to 6 is tested for activity as follows.

##### Rabbit Vas Deferens: Alpha 2 Adrenergic Receptors

New Zealand white rabbits (2-3 kg) are killed by CO<sub>2</sub> inhalation and the vasa deferentia is removed. The prostatic ends of the vasa deferentia (2-3 cm lengths) are mounted between platinum ring electrodes in 9 ml organ baths and bathed in Krebs bicarbonate solution of the following composition (millimolar): NaCl 118.0; KCl 4.7; CaCl<sub>2</sub> 2.5; MgSO<sub>4</sub> 1.2; KH<sub>2</sub> PO<sub>4</sub> 1.2; glucose 11.0; NaHCO<sub>3</sub> 25.0; which solution is maintained at 35° C and bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. The initial tension of the vas deferens is 0.5 g. The tissues are left to equilibrate for 30 minutes before stimulation is started. Vasa are then field stimulated (0.1 Hz, 2 ms pulse width at 90 mA) using a square wave stimulator (WPI A310 Accupulser with

A385 stimulus). The contractions of the tissue are recorded isometrically using Grass FT03 force-displacement transducers and displayed on a Grass Model 7D polygraph. A cumulative concentration-response relationship is obtained for the quinoxaline derivative being tested with a 4 minute contact time at each concentration. Each of the final quinoxaline derivatives of Examples 1 to 5 is effective to reduce the response height. Therefore, such compounds may be properly classified as Alpha 2 agonists since they are also inhibited pharmacologically by treatment with rauwolscine.

#### EXAMPLES 14 to 19

Each of the final quinoxaline derivatives produced in Examples 1 to 6 is tested for renal and blood pressure effects using the following method.

Young male (20-24 weeks old) Sprague-Dawley rats are used. Under ketamine (60 mg/kg b.wt. i.m.) and pentobarbital (i.p. to effect) anesthesia, medical grade plastic tubes are implanted into the abdominal aorta and vena cava via the femoral vessels. In addition, a Silastic-covered stainless steel cannula is sewn in the urinary bladder. After the surgery, the rats are housed individually and are allowed free access to food and water until the day of the experiment.

For about 7 to 10 days before surgery and during recovery, the rats are accustomed to a restraining cage by placement in the cage for 2 to 3 hours every 2nd and 3rd day. The cage is designed for renal clearance studies (a model G Restrainer sold by Braintree Scientific, Inc., Braintree, Massachusetts). The animals' adjustment to the cage is judged by the stability of blood pressure and heart rate.

For an experiment, a rat is placed in the restraining cage, and the arterial line is connected to a Statham pressure transducer and a Beckman Dynograph R61 to monitor

the mean arterial blood pressure, hereinafter referred to as MAP. The venous line is connected to an infusion pump system for infusion of replacement fluid. The quinoxaline derivative is administered intraduodenally by cannula.

- 5 The bladder cannula was extended with a silastic tube to facilitate collection of urine in preweighed tubes. The volume of urine is measured gravimetrically. Body weight is recorded before and after the experiment.

Throughout the experiments, 0.9% NaCl containing 10%  
10 polyfructosan (Inutest) and 1% sodium PAH is infused at a rate of 20 microliters/min. An equilibration period of 60 minutes is followed by two consecutive 30 minute control clearance periods. Then, the quinoxaline derivative is administered for 90 minutes. Urine collection is resumed  
15 10 minutes after the start of quinoxaline derivative administration. By this time the washout of the bladder cannula dead space (approximately 200 microliters) is completed. Three additional clearance measurements are made. Blood samples (150 microliters) are collected at  
20 the midpoint of urine collections. Plasma is separated and saved for analyses, and the cells are resuspended in saline and returned to the animals. Water and sodium loss is carefully replaced i.v. by a variable speed infusion pump.

- 25 Results of these tests indicate that the present quinoxaline derivatives produce renal effects, e.g., increased renal fluid flow. The effect on blood pressure of such derivatives is limited relative to such renal effects.

30 EXAMPLES 20 TO 25

Each of the final quinoxaline derivative produced in Examples 1 to 6 is tested for anti-diarrheal effects and blood pressure effects using the following method.

- Cecectomies are performed in unfasted rats in a  
35 conventional manner. The cecectomized rats are put into

individual wire-bottomed cages placed over sheets of clean paper, and deprived of food and water for the duration of the assay. The MAP is monitored, as described in Examples 17 to 20, throughout the assay. Rats are given a 2 hour  
5 acclimatization period prior to the start of the assay in order to eliminate sporadic episodes of anxiety-induced defecation. During this period they are observed also for consistent occurrences of pelleted feces; an animal producing other than a pelleted stool is disqualified from  
10 the study.


Diarrhea is induced with oral administration of 16,16-dimethyl prostaglandin E<sub>2</sub> (dmPGE<sub>2</sub>) in 3.5% EtOH. The quinoxaline derivative is administered by gavage after the onset of diarrheal episodes. The cage papers are  
15 removed and examined at 30 minute intervals for dmPGE<sub>2</sub>-induced diarrhea. Fecal output is recorded at each interval and fecal consistency is assigned a numerical score in each experimental group as follows: 1= normal pelleted stool; 2= soft-formed stools; 3= water stool  
20 and/or diarrhea. The fecal output index (FOI) is defined as the summation of the number of defecation episodes and their ranked consistency score within an observation period.

Results of these tests indicate that each of the  
25 final quinoxaline derivatives produced in Examples 1 to 5 provides substantial anti-diarrheal effects. Further, such anti-diarrheal effects are produced with relatively limited effects on blood pressure.

While this invention has been described with respect  
30 to various specific examples and embodiments, it is to be understood that the invention is not limited thereto and that it can be variously practiced within the scope of the following claims.

What is Claims is:

1. (Amended) A method of treating a mammal comprising administering to a mammal an effective amount to provide a desired therapeutic effect in said mammal of a compound selected from the group consisting of those having the formula



, and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein  $R_1$  and  $R_2$  each is independently selected from the group consisting of H, alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and  $R_3$ ,  $R_4$  and  $R_5$  each is located in one of the remaining 5-, 6-, 7- and 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms, said desired therapeutic effect being reduction in chronic peripheral pain.

2. The method of claim 1 wherein the 2-imidazolin-2-ylamino group is in the 6- position of the quinoxaline

- nucleus,  $R_3$  is in the 5- position of the quinoxaline nucleus and is selected from the group consisting of Cl, Br and alkyl radicals containing 1 to 3 atoms, and  $R_4$  and  $R_5$  are both H.

3. The method of claim 1 wherein  $R_2$  is a methyl radical.


4. The method of claim 1 wherein  $R_1$  is H and  $R_2$  is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms.

5. The method of claim 2 wherein  $R_2$  is a methyl radical.

6. The method of claim 2 wherein  $R_3$  is Br.

7. The method of claim 5 wherein  $R_3$  is Br.

8. The method of claim 1 wherein said formula is



9. The method of claim 1 wherein  $R_3$  is in the 5- position of the quinoxaline nucleus and is selected from the group consisting of H and alkyl radicals containing 1 to 3 carbon atoms.

10. The method of claim 9 wherein the 2-imidazolin-2-ylamino group is in the 6- position of the quinoxaline

nucleus, and  $R_4$  and  $R_5$  are both H.

11. The method of claim 1 wherein both  $R_1$  and  $R_2$  are H.


12. The method of claim 9 wherein both  $R_1$  and  $R_2$  are H.

13. The method of claim 9 wherein  $R_3$  is selected from the group consisting of H and methyl radical.


14. The method of claim 10 wherein  $R_3$  is selected from the group consisting of H and methyl radical.

15. The method of claim 12 wherein  $R_3$  is selected from the group consisting of H and methyl radical.

16. The method of claim 1 wherein said formula is:



17. The method of claim 1 wherein said formula is:



## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/31087

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K31/495 A61P23/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 10280 A (ALLERGAN INC) 20 April 1995 (1995-04-20) the whole document ---	1-17
X	WO 93 13771 A (ALLERGAN INC) 22 July 1993 (1993-07-22) claims 1-3,9-23; examples ---	1-17
A	US 5 021 416 A (GLUCHOWSKI CHARLES) 4 June 1991 (1991-06-04) cited in the application the whole document ---	1-17
A	US 3 890 319 A (DANIELEWICZ JOHN C ET AL) 17 June 1975 (1975-06-17) cited in the application the whole document ---	1-17
-/--		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 June 2000

Date of mailing of the international search report

19/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Veronese, A

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/31087

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 422 878 A (ALLERGAN INC) 17 April 1991 (1991-04-17) the whole document -----	1-17

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/31087

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9510280 A	20-04-1995	AU 688380 B	12-03-1998
		AU 7798894 A	04-05-1995
		CA 2173974 A	20-04-1995
		EP 0723447 A	31-07-1996
		JP 9506338 T	24-06-1997
		US 5552403 A	03-09-1996
		US 5561132 A	01-10-1996
		US 5587376 A	24-12-1996
		US 5756503 A	26-05-1998
		US 5703077 A	30-12-1997
		US 5714486 A	03-02-1998
		US 5773440 A	30-06-1998
WO 9313771 A	22-07-1993	US 5231096 A	27-07-1993
		AU 3470093 A	03-08-1993
		CA 2127542 A	22-07-1993
		EP 0620732 A	26-10-1994
		JP 7503015 T	30-03-1995
		US 5326763 A	05-07-1994
		US 5373010 A	13-12-1994
		US 5418234 A	23-05-1995
US 5021416 A	04-06-1991	AT 122233 T	15-05-1995
		AU 627626 B	27-08-1992
		AU 6396690 A	09-05-1991
		CA 2025189 A	01-05-1991
		DE 69019297 D	14-06-1995
		DE 69019297 T	12-10-1995
		EP 0426390 A	08-05-1991
		ES 2074138 T	01-09-1995
		HU 57045 A,B	28-11-1991
		IE 68413 B	12-06-1996
		IL 96083 A	10-06-1997
		JP 2999240 B	17-01-2000
		JP 3153626 A	01-07-1991
		NZ 235884 A	22-08-1997
		PH 26978 A	28-12-1992
		SU 1829937 A	23-07-1993
		ZA 9008731 A	31-07-1991
US 3890319 A	17-06-1975	GB 1381979 A	29-01-1975
		AR 213705 A	15-03-1979
		AU 471598 B	29-04-1976
		AU 5198573 A	08-08-1974
		BE 795970 A	27-08-1973
		CA 981678 A	13-01-1976
		CH 577500 A	15-07-1976
		CH 576975 A	30-06-1976
		DE 2309160 A	27-09-1973
		ES 411804 A	01-05-1976
		ES 412102 A	16-05-1976
		FI 63757 B	29-04-1983
		FR 2181776 A	07-12-1973
		IE 37519 B	17-08-1977
		JP 1170985 C	17-10-1983
		JP 48097878 A	13-12-1973
		JP 57054516 B	18-11-1982
		JP 1156372 C	15-07-1983

# INTERNATIONAL SEARCH REPORT

information on patent family members

Inter: onal Application No

PCT/US 99/31087

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3890319 A		JP 56025176 A JP 57045439 B MX 3042 E NL 7302799 A, B SE 417204 B US 4029792 A	10-03-1981 28-09-1982 04-03-1980 31-08-1973 02-03-1981 14-06-1977
EP 0422878 A	17-04-1991	US 5077292 A AT 104973 T AU 628666 B AU 6390090 A CA 2025212 A DE 69008472 D DE 69008472 T DK 422878 T ES 2063289 T HK 1004266 A IE 65784 B JP 2971118 B JP 3145490 A US 5326763 A WO 9213855 A US 5373010 A US 5418234 A US 5112822 A US 5204347 A US 5231096 A US 5198442 A US 5300504 A ZA 9101096 A	31-12-1991 15-05-1994 17-09-1992 18-04-1991 13-04-1991 01-06-1994 15-09-1994 05-09-1994 01-01-1995 20-11-1998 15-11-1995 02-11-1999 20-06-1991 05-07-1994 20-08-1992 13-12-1994 23-05-1995 12-05-1992 20-04-1993 27-07-1993 30-03-1993 05-04-1994 24-12-1991